Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,370,000 shares, an increase of 25.7% from the December 15th total of 2,680,000 shares. Based on an average daily volume of 286,800 shares, the short-interest ratio is presently 11.8 days. Currently, 7.4% of the shares of the company are sold short.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Quest Partners LLC increased its holdings in shares of Astria Therapeutics by 3,310.6% in the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 3,112 shares during the period. PDT Partners LLC purchased a new position in Astria Therapeutics during the third quarter worth about $140,000. SG Americas Securities LLC bought a new position in Astria Therapeutics in the 3rd quarter worth about $155,000. Hsbc Holdings PLC bought a new position in Astria Therapeutics in the 2nd quarter worth about $171,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Astria Therapeutics in the 3rd quarter valued at about $228,000. 98.98% of the stock is owned by institutional investors.

Astria Therapeutics Trading Down 0.5 %

Shares of ATXS stock traded down $0.04 during trading hours on Thursday, reaching $7.75. The stock had a trading volume of 302,803 shares, compared to its average volume of 336,190. The stock’s fifty day simple moving average is $9.60 and its 200 day simple moving average is $10.65. The firm has a market capitalization of $437.36 million, a PE ratio of -3.71 and a beta of 0.70. Astria Therapeutics has a 12 month low of $6.95 and a 12 month high of $16.90.

Analyst Ratings Changes

ATXS has been the topic of several research reports. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research report on Monday. Oppenheimer boosted their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.